{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T10:52:31Z","timestamp":1771671151854,"version":"3.50.1"},"reference-count":82,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T00:00:00Z","timestamp":1604534400000},"content-version":"vor","delay-in-days":309,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2020]]},"DOI":"10.1136\/esmoopen-2020-000842","type":"journal-article","created":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T02:30:20Z","timestamp":1598495420000},"page":"e000842","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Endocrine therapy-based treatments in hormone receptor-positive\/HER2-negative advanced breast cancer: systematic review and network meta-analysis"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1653-3544","authenticated-orcid":false,"given":"Mariana","family":"Brand\u00e3o","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4388-5163","authenticated-orcid":false,"given":"Christian","family":"Maurer","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2851-2011","authenticated-orcid":false,"given":"Patricia Klarmann","family":"Ziegelmann","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1046-6352","authenticated-orcid":false,"given":"Noam F.","family":"Pond\u00e9","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1567-9322","authenticated-orcid":false,"given":"Arlindo","family":"Ferreira","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8461-7256","authenticated-orcid":false,"given":"Samuel","family":"Martel","sequence":"additional","affiliation":[]},{"given":"Martine","family":"Piccart","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9501-4509","authenticated-orcid":false,"given":"Evandro","family":"de Azambuja","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7265-7533","authenticated-orcid":false,"given":"M\u00e1rcio","family":"Debiasi","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1797-5296","authenticated-orcid":false,"given":"Matteo","family":"Lambertini","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1136\/esmoopen-2020-000842_bb0010","author":"Cardoso"},{"key":"10.1136\/esmoopen-2020-000842_bb0015","author":"Howlader"},{"key":"10.1136\/esmoopen-2020-000842_bb0020","author":"Rugo"},{"key":"10.1136\/esmoopen-2020-000842_bb0025","author":"Turner"},{"key":"10.1136\/esmoopen-2020-000842_bb0030","author":"Gourgou-Bourgade"},{"key":"10.1136\/esmoopen-2020-000842_bb0035","unstructured":"Cochrane Handbook for systematic reviews of interventions. Available: https:\/\/training.cochrane.org\/handbook [Accessed 16 Aug 2018]."},{"key":"10.1136\/esmoopen-2020-000842_bb0040","author":"Hutton"},{"key":"10.1136\/esmoopen-2020-000842_bb0045","author":"Lu"},{"key":"10.1136\/esmoopen-2020-000842_bb0050","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/1467-9868.00353","article-title":"Bayesian measures of model complexity and fit","volume":"64","author":"Spiegelhalter","year":"2002","journal-title":"J R Stat Soc Ser B Stat Methodol"},{"key":"10.1136\/esmoopen-2020-000842_bb0055","author":"Salanti"},{"key":"10.1136\/esmoopen-2020-000842_bb0060","author":"Ibrahim"},{"key":"10.1136\/esmoopen-2020-000842_bb0065","author":"Mehta"},{"key":"10.1136\/esmoopen-2020-000842_bb0070","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.SABCS13-S3-07","article-title":"Abstract S3-07: letrozole plus dasatinib improves progression-free survival (PFS) in hormone receptor-positive, HER2-negative postmenopausal metastatic breast cancer (MBC) patients receiving first-line aromatase inhibitor (AI) therapy","volume":"73","author":"Paul","year":"2013","journal-title":"Cancer Res"},{"key":"10.1136\/esmoopen-2020-000842_bb0075","author":"Finn"},{"key":"10.1136\/esmoopen-2020-000842_bb0080","author":"Finn"},{"key":"10.1136\/esmoopen-2020-000842_bb0085","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.1001","article-title":"Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+\/HER2\u2013 advanced breast cancer (PALOMA-1; TRIO-18)","volume":"35","author":"Finn","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2020-000842_bb0090","author":"Finn"},{"key":"10.1136\/esmoopen-2020-000842_bb0095","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.1039","article-title":"Palbociclib (PAL) + letrozole (L) as first-line (1L) therapy (tx) in estrogen receptor-positive (ER+)\/human epidermal growth factor receptor 2-negative (HER2\u2212) advanced breast cancer (ABC): Efficacy and safety across patient (pt) subgroups","volume":"35","author":"Finn","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2020-000842_bb0100","first-page":"P5","volume":"78","author":"Rugo","year":"2018","journal-title":"Cancer Res"},{"key":"10.1136\/esmoopen-2020-000842_bb0105","author":"Turner"},{"key":"10.1136\/esmoopen-2020-000842_bb0110","author":"Hortobagyi"},{"key":"10.1136\/esmoopen-2020-000842_bb0115","author":"Hortobagyi"},{"key":"10.1136\/esmoopen-2020-000842_bb0120","author":"O'Shaughnessy"},{"key":"10.1136\/esmoopen-2020-000842_bb0125","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS16-P4-22-16","article-title":"Abstract P4-22-16: first-line ribociclib + letrozole in patients with HR+, HER2\u2013 advanced breast cancer (ABC) presenting with visceral metastases or bone-only disease: a subgroup analysis of the MONALEESA-2 trial","volume":"77","author":"Burris","year":"2017","journal-title":"Cancer Res"},{"key":"10.1136\/esmoopen-2020-000842_bb0130","author":"Robertson"},{"key":"10.1136\/esmoopen-2020-000842_bb0135","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS16-P2-08-02","article-title":"Abstract P2-08-02: progression-free survival results in patient subgroups from a phase 3 randomized trial of fulvestrant 500 mg vs anastrozole for hormone receptor-positive advanced breast cancer (FALCON)","volume":"77","author":"Robertson","year":"2017","journal-title":"Cancer Res"},{"key":"10.1136\/esmoopen-2020-000842_bb0140","article-title":"Abstract PD5-09: fulvestrant for hormone receptor-positive advanced breast cancer in patients with visceral vs non-visceral metastases: findings from falcon, first, and confirm","volume":"78","author":"Robertson","year":"2018","journal-title":"Cancer Res"},{"key":"10.1136\/esmoopen-2020-000842_bb0145","author":"Johnston"},{"key":"10.1136\/esmoopen-2020-000842_bb0150","author":"Goetz"},{"key":"10.1136\/esmoopen-2020-000842_bb0155","article-title":"Abstract P5-21-02: efficacy and safety of abemaciclib in patients with liver metastases in the MONARCH 1, 2, and 3 studies","volume":"78","author":"Leo","year":"2018","journal-title":"Cancer Res"},{"key":"10.1136\/esmoopen-2020-000842_bb0160","author":"Tripathy"},{"key":"10.1136\/esmoopen-2020-000842_bb0165","author":"Im"},{"key":"10.1136\/esmoopen-2020-000842_bb0170","author":"Bachelot"},{"key":"10.1136\/esmoopen-2020-000842_bb0175","author":"Baselga"},{"key":"10.1136\/esmoopen-2020-000842_bb0180","author":"Campone"},{"key":"10.1136\/esmoopen-2020-000842_bb0185","author":"Yardley"},{"key":"10.1136\/esmoopen-2020-000842_bb0190","author":"Piccart"},{"key":"10.1136\/esmoopen-2020-000842_bb0195","author":"Beck"},{"key":"10.1136\/esmoopen-2020-000842_bb0200","author":"Johnston"},{"key":"10.1136\/esmoopen-2020-000842_bb0205","author":"Burstein"},{"key":"10.1136\/esmoopen-2020-000842_bb0210","author":"Zaman"},{"key":"10.1136\/esmoopen-2020-000842_bb0215","author":"Adelson"},{"key":"10.1136\/esmoopen-2020-000842_bb0220","author":"Turner"},{"key":"10.1136\/esmoopen-2020-000842_bb0225","author":"Cristofanilli"},{"key":"10.1136\/esmoopen-2020-000842_bb0230","author":"Turner"},{"key":"10.1136\/esmoopen-2020-000842_bb0235","author":"O'Shaughnessy"},{"key":"10.1136\/esmoopen-2020-000842_bb0240","author":"Baselga"},{"key":"10.1136\/esmoopen-2020-000842_bb0245","author":"Campone"},{"key":"10.1136\/esmoopen-2020-000842_bb0250","author":"Sledge"},{"key":"10.1136\/esmoopen-2020-000842_bb0255","author":"Musolino"},{"key":"10.1136\/esmoopen-2020-000842_bb0260","author":"Zhao"},{"key":"10.1136\/esmoopen-2020-000842_bb0265","author":"Kornblum"},{"key":"10.1136\/esmoopen-2020-000842_bb0270","author":"Di Leo"},{"key":"10.1136\/esmoopen-2020-000842_bb0275","author":"Kim"},{"key":"10.1136\/esmoopen-2020-000842_bb0280","author":"Schmid"},{"key":"10.1136\/esmoopen-2020-000842_bb0285","author":"Jiang"},{"key":"10.1136\/esmoopen-2020-000842_bb0290","author":"Johnston"},{"key":"10.1136\/esmoopen-2020-000842_bb0295","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS17-GS4-07","article-title":"Abstract GS4-07: results from a randomized placebo-controlled phase 2 trial evaluating exemestane \u00b1 enzalutamide in patients with hormone receptor\u2013positive breast cancer","volume":"78","author":"Krop","year":"2018","journal-title":"Cancer Res"},{"key":"10.1136\/esmoopen-2020-000842_bb0300","author":"Slamon"},{"key":"10.1136\/esmoopen-2020-000842_bb0305","doi-asserted-by":"crossref","first-page":"v856","DOI":"10.1093\/annonc\/mdz394.007","volume":"30","author":"Slamon","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2020-000842_bb0310","author":"Wolff"},{"key":"10.1136\/esmoopen-2020-000842_bb0315","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.1005","article-title":"Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER-positive breast cancer (FAKTION): a randomized, double-blind, placebo-controlled, phase II trial","volume":"37","author":"Jones","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2020-000842_bb0320","author":"Rugo"},{"key":"10.1136\/esmoopen-2020-000842_bb0325","author":"Krop"},{"key":"10.1136\/esmoopen-2020-000842_bb0330","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.18_suppl.LBA1006","article-title":"Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA -mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER","volume":"36","author":"Baselga","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2020-000842_bb0335","doi-asserted-by":"crossref","first-page":"viii709","DOI":"10.1093\/annonc\/mdy424.010","article-title":"Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): results of the phase III SOLAR-1 trial","volume":"29","author":"Andr\u00e9","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2020-000842_bb0340","author":"Robson"},{"key":"10.1136\/esmoopen-2020-000842_bb0345","author":"Martel"},{"key":"10.1136\/esmoopen-2020-000842_bb0350","author":"Cherny"},{"key":"10.1136\/esmoopen-2020-000842_bb0355","author":"Chaimani"},{"key":"10.1136\/esmoopen-2020-000842_bb0360","author":"Zhang"},{"key":"10.1136\/esmoopen-2020-000842_bb0365","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.2147\/OTT.S165681","article-title":"Effect of first-line endocrine therapy in patients with hormone-sensitive advanced breast cancer: a network meta-analysis","volume":"11","author":"Zhang","year":"2018","journal-title":"OncoTargets Ther"},{"key":"10.1136\/esmoopen-2020-000842_bb0370","author":"Ayyagari"},{"key":"10.1136\/esmoopen-2020-000842_bb0375","author":"Telford"},{"key":"10.1136\/esmoopen-2020-000842_bb0380","author":"Ayyagari"},{"key":"10.1136\/esmoopen-2020-000842_bb0385","author":"Zhang"},{"key":"10.1136\/esmoopen-2020-000842_bb0390","author":"Chirila"},{"key":"10.1136\/esmoopen-2020-000842_bb0395","author":"Generali"},{"key":"10.1136\/esmoopen-2020-000842_bb0400","author":"Wilson"},{"key":"10.1136\/esmoopen-2020-000842_bb0405","author":"Giuliano"},{"key":"10.1136\/esmoopen-2020-000842_bb0410","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS17-PD5-10","article-title":"Abstract PD5-10: a first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-0927, in postmenopausal women with estrogen receptor positive (ER+) HER2-negative metastatic breast cancer (BC)","volume":"78","author":"Dickler","year":"2018","journal-title":"Cancer Res"},{"key":"10.1136\/esmoopen-2020-000842_bb0415","author":"Chino"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920326624?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920326624?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/esmoopen-2020-000842","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:23:44Z","timestamp":1761855824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702920326624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":82,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"alternative-id":["S2059702920326624"],"URL":"https:\/\/doi.org\/10.1136\/esmoopen-2020-000842","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Endocrine therapy-based treatments in hormone receptor-positive\/HER2-negative advanced breast cancer: systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/esmoopen-2020-000842","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 THE AUTHORS. Published by Elsevier Limited on behalf of European Society for Medical Oncology; Originally published by BMJ.","name":"copyright","label":"Copyright"}],"article-number":"e000842"}}